Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
Shinkichi Takamori 1 2, Takashi Seto 1, Masafumi Yamaguchi 3, Fumihiko Kinoshita 1, Takatoshi Fujishita 1, Kensaku Ito 1, Ryo Toyozawa 1, Fumihiro Shoji 1, Tatsuro Okamoto 1

We described a patient with lung adenocarcinoma harboring METex14del as a potential acquired resistance to osimertinib, who responded to subsequent tepotinib therapy. Re-biopsy and re-analysis of genetic profiles should be considered in NSCLC patients who develop osimertinib resistance.

Front Oncol. 2022 Oct 13;12:965741.

Washout DNA copy number analysis by low-coverage whole genome sequencing for assessment of thyroid FNAs
Linfeng Wu 1, Yuying Zhou 1, Yaoyao Guan 2, Rongyao Xiao 1, Jiaohao Cai 1, Weike Chen 1, Mengmeng Zheng 1, Kaiting Sun 1, Chao Chen 1, Guanli Huang 3, Xiaogang Zhang 4 5, Lijuan Zhai 4 5, Ziliang Qian 5 6, Shu-Rong Shen 1

It is feasible to identify high-risk LN metastasis thyroid cancer from FNA washout samples preoperatively using wDNA CNV profiling using LC-WGS.

Front Endocrinol (Lausanne). 2022 Oct 14;13:888072. 

Evidence supporting the oncogenic role of BAZ1B in colorectal cancer
Aleksandra Grochowska 1 2, Malgorzata Statkiewicz 1, Maria Kulecka 1 2, Magdalena Cybulska 1, Zuzanna Sandowska-Markiewicz 1, Michal Kopczynski 1, Edyta Drezinska-Wolek 3, Andrzej Tysarowski 3, Monika Prochorec-Sobieszek 3, Jerzy Ostrowski 1 2, Michal Mik

These findings were reproduced when both cell lines were grown as xenografts. RNA-Seq of HCT116 and SW480 xenografts identified 2046 and 99 differentially expressed genes (DEGs) (adjusted P ≤ 0.05), respectively. Functional annotation of DEGs identified already established as well as new molecular processes dependent on BAZ1B protein expression. In conclusion, BAZ1B is overexpressed in CRC tissue and contributes to CRC cell proliferation in vitro and in vivo. The data support the emerging oncogenic role of BAZ1B in cancerogenesis including in CRC.

Am J Cancer Res. 2022 Oct 15;12(10):4751-4763

Assessing and Evaluating the Scope and Constraints of Idylla Molecular Assays by Using Different Source Materials in Routine Diagnostic Settings
Sanga Mitra Boppudi 1 2, Stefanie Scheil-Bertram 1, Elisabeth Faust 1, Anil Annamneedi 3 4, Annette Fisseler-Eckhoff 1 2

All the assays tested with FFPE sections and gDNA/RNA input showed above 96% accuracy and sensitivity,individually with 100% specificity. The Idylla assays also performed exceptionally well on the archival FFP Etissues, and the use of assays for other solid tumors was also remarkable. The performance test and accuracy of Idylla assays showed high efficiency with certain limitations. For the use of Idylla assays,both qualitative and quantitative applicability of different tumor source materials could produce efficient results in different diagnostic settings within a short TAT.

Int J Mol Sci. 2022 Oct 19;23(20):12515. 

Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
Moonsik Kim1, Changseon Lee2 , Juyeon Hong2, Juhee Kim3 , Ji Yun Jeong1, Nora Jee-Young Park1, Ji-Eun Kim1, Ji Young Park1

ONCOaccuPanel demonstrated high analytical sensitivity, reproducibility, and repeatability and is feasible for the detection of clinically relevant mutations in clinical settings.

Cancer Res Treat. 2022 Nov 25. doi: 10.4143/crt.2022.891. 

The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC
Vladimír Koucký 1 2, Kamila Hladíková 3, Eliška Táborská 3, Jan Bouček 4, Marek Grega 5, Radek Špíšek 3, Anna Fialová

our study indicates that the immunosuppressive cytokine milieu rich in IL-10 and TNFα in HPV-negative but not in

HPV-positive HNSCC significantly affects the functional capacity of tumor-infiltrating pDCs, and such dysfunctional

pDCs may further support the immunosuppressive tumor microenvironment by promoting the expansion of Tregs

in the tumor tissue.

Cancer Immunol Immunother. 2021 Feb 11.